Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Linkou, Taiwan.
Endocr Pathol. 2015 Mar;26(1):80-6. doi: 10.1007/s12022-015-9357-8.
The incidence and histopathological characteristics of metastatic cancers to the thyroid (MCT) are different in various geographic areas. The aim of this study was to elucidate the clinical features of MCT, including histocytological diagnosis and therapeutic outcomes. A retrospective analysis of patients with thyroid cancer treated and followed up at the Chang Gung Medical Center in Linkou was performed. Among 3957 patients with thyroid cancer, a total of 56 patients with MCT were evaluated. Of them, 47 patients (83.9 %) were diagnosed with malignancy or suspected malignancy via fine needle aspiration cytology of the thyroid. Synchronous primary cancers were diagnosed in 44 of the patients with MCT. Of the MCT, metastasis of lung cancer to the thyroid was the leading category. Other primary sites of MCT were the head and neck, gastrointestinal tract, kidneys, breast, cervix, and unknown primary site. The mean 5-, 10-, 20-, and 60-month survival rates were 46.4, 32.1, 21.4, and 7.9 % for the patients. Patients with metachronous thyroid carcinoma had significantly better survival than patients with synchronous cancer. In conclusions, the incidence of MCT in patients with thyroid cancer is low; however, the prognosis of patients with MCT is poor, especially in patients diagnosed with synchronous primary tumors. In this study, MCT commonly originated in organs located near the thyroid, such as the lungs, head, and neck. Close monitoring of these malignancies may improve the prognosis of patients with MCT in the future.
甲状腺转移癌（MCT）的发病率和组织病理学特征在不同地理区域有所不同。本研究旨在阐明 MCT 的临床特征，包括组织细胞学诊断和治疗结果。对在林口长庚纪念医院接受治疗和随访的甲状腺癌患者进行回顾性分析。在 3957 例甲状腺癌患者中，共有 56 例 MCT 患者进行了评估。其中，47 例（83.9%）通过甲状腺细针抽吸细胞学检查诊断为恶性或疑似恶性肿瘤。44 例 MCT 患者同时诊断出原发性癌症。在 MCT 中，肺癌转移至甲状腺最为常见。其他 MCT 的原发部位为头颈部、胃肠道、肾脏、乳腺、宫颈和未知原发部位。MCT 患者的 5、10、20 和 60 个月生存率分别为 46.4%、32.1%、21.4%和 7.9%。患有不同时性甲状腺癌的患者的生存率明显高于患有同时性癌症的患者。总之，甲状腺癌患者中 MCT 的发病率较低；然而，MCT 患者的预后较差，特别是同时诊断出原发性肿瘤的患者。在这项研究中，MCT 通常起源于甲状腺附近的器官，如肺、头和颈部。密切监测这些恶性肿瘤可能会改善未来 MCT 患者的预后。
